176 related articles for article (PubMed ID: 35452143)
21. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
Bauduer F; Recanzone H
Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
[TBL] [Abstract][Full Text] [Related]
22. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
Braga Lemos M; Rodrigues SR; Schroeder T; Kulasekararaj AG; Matos JE; Tang D
Eur J Haematol; 2021 Jul; 107(1):3-23. PubMed ID: 33715214
[TBL] [Abstract][Full Text] [Related]
23. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
24. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
25. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
[TBL] [Abstract][Full Text] [Related]
26. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
27. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
28. Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Finelli C; Parisi S; Paolini S
Expert Rev Hematol; 2022 May; 15(5):411-421. PubMed ID: 35549626
[TBL] [Abstract][Full Text] [Related]
29. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Kelaidi C; Stamatoullas A; Beyne-Rauzy O; Raffoux E; Quesnel B; Guerci A; Dreyfus F; Brechignac S; Berthou C; Prebet T; Hicheri Y; Hacini M; Delaunay J; Gourin MP; Camo JM; Zerazhi H; Taksin AL; Legros L; Choufi B; Fenaux P;
Haematologica; 2010 Jun; 95(6):892-9. PubMed ID: 20015890
[TBL] [Abstract][Full Text] [Related]
30. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.
McQuilten ZK; Polizzotto MN; Wood EM; Sundararajan V
Transfusion; 2013 Aug; 53(8):1714-21. PubMed ID: 23305556
[TBL] [Abstract][Full Text] [Related]
32. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
33. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes and the role of iron overload.
Harvey RD
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
[TBL] [Abstract][Full Text] [Related]
35. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
[TBL] [Abstract][Full Text] [Related]
37. The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients.
Xhaard A; Miekoutima E; Pirenne F; François A; Tiberghien P; Sebert M; Adès L; Fenaux P; Leprêtre AC
Vox Sang; 2022 May; 117(5):693-700. PubMed ID: 34985763
[TBL] [Abstract][Full Text] [Related]
38. [Transfusions in myelodysplastic syndromes].
Rose C
Transfus Clin Biol; 2017 Sep; 24(3):209-215. PubMed ID: 28651884
[TBL] [Abstract][Full Text] [Related]
39. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
40. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
